PRNewsWire
16 Apr 2026, 14:00 UTC · 22w ago
Verdict
Headline takes no side. We score PEPG −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Analysts noted a lack of meaningful improvement in patient handgrip strength or 10-meter walk/run tests from PepGen's Phase 2 FREEDOM2-DM1 trial data.
More negative than 98% of claims this week
The FDA placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 trial due to questions regarding preclinical pharmacology and toxicology studies.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
Pomerantz LLP is investigating PepGen Inc. for potential securities fraud or unlawful business practices.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing an FDA clinical hold, poor clinical data, a massive stock price collapse, and a securities fraud investigation.
More negative than 80% of ticker scores this week
The company is the subject of a securities fraud investigation by Pomerantz LLP.
More negative than 80% of ticker scores this week
The company is the subject of a securities fraud investigation by Pomerantz LLP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
45m ago
+68.9%
Price is moving against the score
$2.90 vs $1.72 close before publication (Apr 15) · not market-adjusted
PEPG chart →
